HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor. The study will investigate DLT of HRYZ-T101 TCR-T cell injection.
Epistemonikos ID: 38bc677e97645ff6e5db7182307037a9c40c1a16
First added on: May 14, 2024